BRAF and neoplasm: In its absence, the effects of MEK inhibitors have been studied in tumors expressing mutated BRAF and KRAS; however, they led to tumor resistance through feedback and crosstalk mechanisms within the EGFR/MAPK and EGFR/PI3K signaling pathway3–6.